翰森製藥(03692.HK)中期歸母淨利下降5.73%至12.22億元
格隆匯 8 月 26日丨翰森製藥(03692.HK)發佈公告,截至2020年6月30日止六個月,集團實現收入39.8億元(人民幣,單位下同),同比下降13.5%;毛利36.22億元,同比下降14.13%;母公司擁有人應占溢利12.22億元,同比下降5.73%;每股基本盈利0.21元;擬派發中期股息每股港仙。
公告表示,集團的絕大部分收入來自於藥品的銷售。集團大部分主要產品集中在集團策略性專注的主要治療領域,即中樞神經系統疾病、抗腫瘤、抗感染及其他領域。在新冠疫情以及帶量集中採購政策的影響下,集團的總收入同比減少,但新上市的產品收入快速增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.